Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H28O2 |
Molecular Weight | 288.4244 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CCC4=CC(=O)CC[C@]34C
InChI
InChIKey=MUMGGOZAMZWBJJ-DYKIIFRCSA-N
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
Molecular Formula | C19H28O2 |
Molecular Weight | 288.4244 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00624Curator's Comment: Description was created based on several sources, including
Sources: http://www.drugbank.ca/drugs/DB00624
Curator's Comment: Description was created based on several sources, including
Testosterone is a steroid sex hormone found in both men and women. In men, testosterone is produced primarily by the Leydig (interstitial) cells of the testes when stimulated by luteinizing hormone (LH). It functions to stimulate spermatogenesis, promote physical and functional maturation of spermatozoa, maintain accessory organs of the male reproductive tract, support development of secondary sexual characteristics, stimulate growth and metabolism throughout the body and influence brain development by stimulating sexual behaviors and sexual drive. In women, testosterone is produced by the ovaries (25%), adrenals (25%) and via peripheral conversion from androstenedione (50%). Testerone in women functions to maintain libido and general wellbeing. Testosterone exerts a negative feedback mechanism on pituitary release of LH and follicle-stimulating hormone (FSH). Testosterone may be further converted to dihydrotestosterone or estradiol depending on the tissue. The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects. Testosterone is used as hormone replacement or substitution of diminished or absent endogenous testosterone. Use in males: For management of congenital or acquired hypogonadism, hypogonadism associated with HIV infection, and male climacteric (andopause). Use in females: For palliative treatment of androgen-responsive, advanced, inoperable, metastatis (skeletal) carcinoma of the breast in women who are 1-5 years postmenopausal; testosterone esters may be used in combination with estrogens in the management of moderate to severe vasomotor symptoms associated with menopause in women who do not respond to adequately to estrogen therapy alone.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17635942 |
|||
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19856921 |
3.16 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TESTOSTERONE Approved UseTestosterone is an androgen indicated for replacement therapy in males for
conditions associated with a deficiency or absence of endogenous
testosterone:
• Primary Hypogonadism (Congenital or Acquired) (1)
• Hypogonadotropic Hypogonadism (Congenital or Acquired) Launch Date1.35950395E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.1 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10902784/ |
8.2 mg single, topical dose: 8.2 mg route of administration: Topical experiment type: SINGLE co-administered: |
TESTOSTERONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
214 ng/dL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01725451 |
30 mg single, topical dose: 30 mg route of administration: topical experiment type: single co-administered: |
TESTOSTERONE unknown | Homo sapiens population: healthy age: sex: food status: |
|
231 ng/dL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01725451 |
30 mg single, topical dose: 30 mg route of administration: topical experiment type: single co-administered: |
TESTOSTERONE unknown | Homo sapiens population: healthy age: sex: food status: |
|
930.1 ng/dL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01386606 |
5 g 1 times / day multiple, topical dose: 5 g route of administration: topical experiment type: multiple co-administered: |
TESTOSTERONE unknown | Homo sapiens |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
948 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10902784/ |
8.2 mg single, topical dose: 8.2 mg route of administration: Topical experiment type: SINGLE co-administered: |
TESTOSTERONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
2120 ng*h/dL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01725451 |
30 mg single, topical dose: 30 mg route of administration: topical experiment type: single co-administered: |
TESTOSTERONE unknown | Homo sapiens population: healthy age: sex: food status: |
|
3110 ng*h/dL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01725451 |
30 mg single, topical dose: 30 mg route of administration: topical experiment type: single co-administered: |
TESTOSTERONE unknown | Homo sapiens population: healthy age: sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10902784/ |
8.2 mg single, topical dose: 8.2 mg route of administration: Topical experiment type: SINGLE co-administered: |
TESTOSTERONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10902784/ |
8.2 mg single, topical dose: 8.2 mg route of administration: Topical experiment type: SINGLE co-administered: |
TESTOSTERONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
75 mg 1 times / day steady, subcutaneous (median) Recommended Dose: 75 mg, 1 times / day Route: subcutaneous Route: steady Dose: 75 mg, 1 times / day Sources: |
unhealthy, adult n = 150 Health Status: unhealthy Condition: hypogonadism Age Group: adult Sex: M Population Size: 150 Sources: |
Disc. AE: Hypertension... AEs leading to discontinuation/dose reduction: Hypertension (5.6%) Sources: |
100 mg 1 times / day steady, topical Recommended Dose: 100 mg, 1 times / day Route: topical Route: steady Dose: 100 mg, 1 times / day Sources: |
unhealthy, mean 74 years n = 106 Health Status: unhealthy Condition: with limitations in mobility Age Group: mean 74 years Sex: M Population Size: 106 Sources: |
Other AEs: Cardiac disorders, Atherosclerosis... Other AEs: Cardiac disorders (6.5%) Sources: Atherosclerosis (6.4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypertension | 5.6% Disc. AE |
75 mg 1 times / day steady, subcutaneous (median) Recommended Dose: 75 mg, 1 times / day Route: subcutaneous Route: steady Dose: 75 mg, 1 times / day Sources: |
unhealthy, adult n = 150 Health Status: unhealthy Condition: hypogonadism Age Group: adult Sex: M Population Size: 150 Sources: |
Atherosclerosis | 6.4% | 100 mg 1 times / day steady, topical Recommended Dose: 100 mg, 1 times / day Route: topical Route: steady Dose: 100 mg, 1 times / day Sources: |
unhealthy, mean 74 years n = 106 Health Status: unhealthy Condition: with limitations in mobility Age Group: mean 74 years Sex: M Population Size: 106 Sources: |
Cardiac disorders | 6.5% | 100 mg 1 times / day steady, topical Recommended Dose: 100 mg, 1 times / day Route: topical Route: steady Dose: 100 mg, 1 times / day Sources: |
unhealthy, mean 74 years n = 106 Health Status: unhealthy Condition: with limitations in mobility Age Group: mean 74 years Sex: M Population Size: 106 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
yes | |||
Page: - |
yes |
Drug as victim
PubMed
Title | Date | PubMed |
---|---|---|
Cross-talk between 2,3,7,8-tetrachlorodibenzo-p-dioxin and testosterone signal transduction pathways in LNCaP prostate cancer cells. | 1999 Mar 24 |
|
Steroid feedback on gonadotropin release and pituitary gonadotropin subunit mRNA in mice lacking a functional estrogen receptor alpha. | 1999 Oct |
|
Circadian expression of the steroid 15 alpha-hydroxylase (Cyp2a4) and coumarin 7-hydroxylase (Cyp2a5) genes in mouse liver is regulated by the PAR leucine zipper transcription factor DBP. | 1999 Oct |
|
Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. | 2000 Aug |
|
Changes in serum and tissue zinc levels in sex hormone-induced prostatic carcinogenesis in the noble rat. | 2000 Nov-Dec |
|
Psychophysiological responses to the Stroop Task after a maximal cycle ergometry in elite sportsmen and physically active subjects. | 2001 Feb |
|
Castration in Gambel's and Scaled Quail: ornate plumage and dominance persist, but courtship and threat behaviors do not. | 2001 Feb |
|
Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. | 2001 Feb |
|
Substitution mutation C268Y causes 17 beta-hydroxysteroid dehydrogenase 3 deficiency. | 2001 Feb |
|
Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause. | 2001 Feb |
|
Muting of androgen negative feedback unveils impoverished gonadotropin-releasing hormone/luteinizing hormone secretory reactivity in healthy older men. | 2001 Feb |
|
Estrogen and androgen elicit growth hormone release via dissimilar patterns of hypothalamic neuropeptide secretion. | 2001 Feb |
|
Testosterone concentrations in women aged 25-50 years: associations with lifestyle, body composition, and ovarian status. | 2001 Feb 1 |
|
Changes in androgenic steroid profile due to urine contamination by microorganisms: a prospective study in the context of doping control. | 2001 Feb 15 |
|
Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. | 2001 Jan |
|
Long-term remission of ovarian hyperandrogenism after short-term treatment with a gonadotropin-releasing hormone agonist. | 2001 Jan |
|
Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. | 2001 Jan |
|
Targeted disruption of luteinizing hormone/human chorionic gonadotropin receptor gene. | 2001 Jan |
|
The female-to-male transsexual patient: a source of human ovarian cortical tissue for experimental use. | 2001 Jan |
|
Short-term 17beta-estradiol decreases glucose R(a) but not whole body metabolism during endurance exercise. | 2001 Jan |
|
Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride. | 2001 Jan |
|
Sex steroid hormones enhance immune function in male and female Siberian hamsters. | 2001 Jan |
|
Rapid and reversible inhibition of brain aromatase activity. | 2001 Jan |
|
Anorexia, body composition, and ageing. | 2001 Jan |
|
Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. | 2001 Jan |
|
Novel approaches to female sexual dysfunction. | 2001 Jan |
|
Cross-talk between steroid-receptor-mediated and cell-membrane-receptor-mediated signalling pathways results in the in vivo modulation of c-Met and ornithine decarboxylase gene expression in mouse kidney. | 2001 Jan 15 |
|
Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3). | 2001 Jan 22 |
|
Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. | 2001 Jan 9 |
|
Regulation of the steroid-inducible 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase gene in Comamonas testosteroni. | 2001 Mar 30 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: can also be injected https://www.drugs.com/pro/testosterone.html
Starting dose of testosterone gel is 50 mg of testosterone (4 pump
actuations, two 25 mg packets, or one 50 mg packet), applied once
daily in the morning.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26566264
10 nM Testosterone significantly reduced secretion of BDNF in in human airway smooth muscle
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:41:59 UTC 2022
by
admin
on
Fri Dec 16 16:41:59 UTC 2022
|
Record UNII |
3XMK78S47O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
52590
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
49043-3
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
NDF-RT |
N0000175824
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
2990-0
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
76352-4
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
2986-8
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
WHO-VATC |
QG03EA02
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
34380-6
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
83116-4
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
59229-5
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
25987-9
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
LIVENSA (SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL )
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
26827-6
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LIVERTOX |
944
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
26826-8
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
CFR |
21 CFR 862.1680
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
2987-6
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
NCI_THESAURUS |
C2298
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
NDF-RT |
N0000008241
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
2993-4
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
49041-7
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
2994-2
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
13486-6
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
FDA ORPHAN DRUG |
104197
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
35225-2
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
49042-5
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
59240-2
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
FDA ORPHAN DRUG |
523916
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
59233-7
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
FDA ORPHAN DRUG |
855921
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
WHO-VATC |
QG03BA03
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
2988-4
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
16286-7
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
WIKIPEDIA |
Designer-drugs-Testosterone
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
15095-3
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
31030-0
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
WHO-ATC |
G03EA02
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
WHO-ATC |
G03BA03
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
73570-4
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
2984-3
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
15432-8
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
2991-8
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
14914-6
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
41018-3
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
35224-5
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
2992-6
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
17685-9
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
59219-6
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
INTRINSA (WITHDRAWN: SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL)
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
48357-8
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
FDA ORPHAN DRUG |
94595
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
10631-0
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
51005-7
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
18.2
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
27306-0
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
CFR |
21 CFR 862.1430
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
70239-9
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
CFR |
21 CFR 310.528
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
70240-7
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
15094-6
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
2985-0
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
2989-2
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
6891-6
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
83115-6
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
14913-8
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
17687-5
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
DEA NO. |
4000
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
LOINC |
25986-1
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
||
|
NDF-RT |
N0000000146
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3XMK78S47O
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
9700
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
17347
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
200-370-5
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
TESTOSTERONE
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
58-22-0
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
D013739
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
3398
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
2858
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
DB00624
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
1900
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
C862
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
3XMK78S47O
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
1646009
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
6013
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
Testosterone (medication)
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
CHEMBL386630
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
Testosterone
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
DTXSID8022371
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
10379
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | RxNorm | ||
|
SUB10937MIG
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
2607
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | |||
|
M10594
Created by
admin on Fri Dec 16 16:42:00 UTC 2022 , Edited by admin on Fri Dec 16 16:42:00 UTC 2022
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR | |||
|
ENZYME->SUBSTRATE |
Vmax
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
In reproductive tissues, dihydrotestosterone is further metabolized to 3-alpha and 3-beta androstanediol
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE TOXIC -> PARENT |
Metabolite shown to induce pyrogenic and inflammatory reactions in man.
|
||
|
PARENT -> METABOLITE |
URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
DHT binds with greater affinity to SHBG than does testosterone
MAJOR
|
||
|
METABOLITE -> PARENT |
In reproductive tissues, dihydrotestosterone is further metabolized to 3-alpha and 3-beta androstanediol
|
||
|
METABOLITE -> PARENT |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
By glucuronosyl transferase (UGT)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|